Tag Archives: ADC

Arduino Diecimila Board Access…

By wisecracker

This is a very simple starter DEMO to access Arduino Diecimila Board for the
Macbook Pro 13″ OSX 10.7.5…
A potentiometer is connected between 5V and Gnd with the wiper connected to
ANALOG IN 0 on the Arduino. This was adjusted to give the Ms and Ls as seen…

I now have DC in for this machine AND Linux too as on my Linux tools the device
becomes /dev/ttyUSB0 …

NOTE:- The device below is for MY machine and WILL be different for yours…

It is assumed that you have a Terminal up and running AND you have NOT
plugged in your USB Arduino Board yet…

Enjoy finding simple solutions to often very difficult problems…

Public Domain and you may do with it as you please…

Code:

Last login: Thu Jul 18 21:58:14 on ttys000
AMIGA:barrywalker~> # Find the USB device first.
AMIGA:barrywalker~> ls /dev/*usb*
ls: /dev/*usb*: No such file or directory
AMIGA:barrywalker~> # Now plug in the Arduino Diecimila Board...
AMIGA:barrywalker~> ls /dev/*usb*
/dev/cu.usbserial-A7007cvs /dev/tty.usbserial-A7007cvs
AMIGA:barrywalker~> # USE the /dev/cu.usbserial-A7007cvs device...
AMIGA:barrywalker~> cat < /dev/cu.usbserial-A7007cvs
MLMMLMMMMMMLMMMMLMLMMLLLLLLMLLMMMMMLMMMLMLLMLMLMMMMMMMMMMMLLMLLLMLLLLLLMLLLMLLM
MMMLMLLMLMMMLMMMMMLMLMLMLMMMLLLMMLLMMMMMMLLLMLLMMLMLLLLLMMMMLMLLLLMMMMMMMLLLMML
MMLMMMLLMLMLMLLMMMMLLLMLMMMMMLLMMLMMMLLMMMLLMMMMMMMMMMLLMLLLMMLLLMLMLMMLMMLMLML
MMMMMLLMMMMLLLLLLMMMMMMLLMLMMMMMLMMMLLMLMLMLLMLMLLLLMMMLMMLMMMMLMLMLMMLMMLMLMML
MLMLLLMLLLLLLMLLMMLMMMLMMMLMMLMLMMLMLMLMMLMLMMMLLLMLMLLLMMLLLMLMLMLLLLLLLMLMMML
LMcMMLLLLMLMMMMLMMMMMLMMLLMLMMMMMMLMLLMMMMMLMMMMLMLLMLMMMLLLMMMMMLLLMLMMLMLMMLM
MLMLLMLMMMMMLLLMMMMLLLMLMMLLMMLLMLLLMMMLLMMMLLMLLLLMMLLMMMMLLMMMMMLLLLLMMLLMMML
MLMMLLLMLLLLM^C
AMIGA:barrywalker~> _


The .PDE file for the Arduino as a test piece, this uses an early version of the
programming SW and I know it won’t compile on current versions so you will have
to modify slightly as required…

Code:

/* Using the Arduino as a DEMO single channel ADC for Windows (TM), Linux, */
/* AMIGA, WinUAE and now the Macbook Pro 13 inch OSX 10.7.5... */

/* Set up a variable for basic analogue input. */
int analogue0 = 0;

void setup() {
/* Open the serial port at 9600 bps. */
Serial.begin(9600);

/* Set the analogue voltage reference, DEFAULT is 5V in this case. */
analogReference(DEFAULT);
}

void loop() {
/* Read the 10 bit analogue voltage on analogue input 0. */
analogue0 = analogRead(0);
/* Convert to a byte value by dividing by 4. */
analogue0 = analogue0/4;

/* Send to the Serial Port the byte value. */
Serial.print(analogue0, BYTE);
}


…read more

Source: FULL ARTICLE at The UNIX and Linux Forums

Seattle Genetics to Host Conference Call and Webcast Discussion of First Quarter 2013 Financial Resu

By Business Wirevia The Motley Fool

Filed under:

Seattle Genetics to Host Conference Call and Webcast Discussion of First Quarter 2013 Financial Results on May 7, 2013

BOTHELL, Wash.–(BUSINESS WIRE)– Seattle Genetics, Inc. (NAS: SGEN) announced today that it will report its first quarter 2013 financial results on Tuesday, May 7, 2013, after the close of financial markets. Following the announcement, company management will host a conference call and webcast discussion of the results and provide a general corporate update. Access to the event can be obtained as follows:

LIVE access on Tuesday, May 7, 2013
1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time

REPLAY access

  • Telephone replay will be available beginning at approximately 3:30 p.m. PT on Tuesday, May 7, 2013 through 5:00 p.m. PT on Thursday, May 9, 2013 by calling 800-406-7325 (domestic) or 303-590-3030 (international); conference ID 4614604
  • Webcast replay will be available on the Seattle Genetics website at http://www.seattlegenetics.com/ in the Investors and News section

About Seattle Genetics

Seattle Genetics is a biotechnology company focused on the development and commercialization of monoclonal antibody-based therapies for the treatment of cancer. The company’s lead program, ADCETRIS® (brentuximab vedotin), received accelerated approval from the U.S. Food and Drug Administration in August 2011 and approval with conditions from Health Canada in February 2013 for two indications. In addition, under a collaboration with Millennium: The Takeda Oncology Company, ADCETRIS received conditional marketing authorization from the European Commission in October 2012. Seattle Genetics also has four other clinical-stage ADC programs: SGN-75, ASG-5ME, ASG-22ME and SGN-CD19A. Seattle Genetics has collaborations for its ADC technology with a number of leading biotechnology and pharmaceutical companies, including Abbott, Agensys (an affiliate of Astellas), Bayer, Celldex Therapeutics, Daiichi Sankyo, Genentech, GlaxoSmithKline, Millennium, Pfizer and Progenics, as well as ADC co-development agreements with Agensys and Genmab. More information can be found at www.seattlegenetics.com.

Preclinical Data Presented at AACR Describe a Mechanism of Action of Cabozantinib in a Prostate Canc

By Business Wirevia The Motley Fool

Filed under:

Preclinical Data Presented at AACR Describe a Mechanism of Action of Cabozantinib in a Prostate Cancer Bone Metastasis Model

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)– Exelixis, Inc. (NAS: EXEL) announced the presentation of preclinical data that provide insight into the mechanism of action of its lead compound, cabozantinib, with respect to its activity against prostate cancer tumors that have metastasized to the bone. Timothy Graham, a researcher at The Institute of Cancer Research in London, UK, presented the data (abstract #3924) today in a poster presentation session at the American Association for Cancer Research (AACR) Annual Meeting 2013, which is being held April 6-10, 2013, in Washington, D.C.

Previously reported clinical findings with cabozantinib in castration-resistant prostate cancer (CRPC) patients with bone metastases have included a 67% rate of bone scan response, reduced 99Tc-MDP uptake, and reductions in plasma markers of osteoclast activity. In addition, an increase in tumor apparent diffusion coefficient (ADC) measured using diffusion-weighted MRI was reported in a cabozantinib-treated CRPC patient with a bone scan response. Based on these observations, studies of cabozantinib in preclinical models of prostate cancer bone metastases were undertaken to understand the mechanism(s) of action underlying these effects.

In the poster presented today, the investigators reported on a refined prostate cancer bone metastasis model that develops many of the features associated with bone metastases in CRPC patients. In this model, injection of VCaP prostate cancer cells expressing luciferase (to allow bioluminescent imaging of tumors) into the tibiae of mice induced aberrant bone remodeling and development of tumor bone lesions. Both histological analysis of tissue sections and radiological imaging showed the development of extensive osteosclerosis, with abnormal new bone protruding from the tibiae as well as osteolysis resulting in destruction of normal bone structures. This was accompanied by increased numbers of osteoclasts at the sites of bone remodeling. A large increase in 99Tc-methylene diphosphonate (MDP) uptake was observed at the site of the bone lesions as measured by single photon emission computed tomography (SPECT) imaging. 99Tc-MDP bone scans are routinely employed in clinical practice to detect bone metastases in CRPC patients.

Treatment of tumor-bearing animals with cabozantinib resulted in rapid and substantial inhibition of tumor growth evident by both bioluminescent and magnetic resonance imaging (MRI) techniques. Monitoring tumors in cabozantinib-treated animals using diffusion-weighted MRI showed a significant increase in the apparent diffusion coefficient (ADC) compared to tumors in vehicle-treated animals. Increases in ADC are the result of increased mobility of water molecules in the tumor, and have been shown to correlate with tumor cell death. Consistent with these findings, histological …read more

Source: FULL ARTICLE at DailyFinance

Seattle Genetics and Collaborators Highlight Multiple Antibody-Drug Conjugate (ADC) Programs and Tec

By Business Wirevia The Motley Fool

Filed under:

Seattle Genetics and Collaborators Highlight Multiple Antibody-Drug Conjugate (ADC) Programs and Technology Advances at AACR

– Presentations Highlight Preclinical Data for Novel SGN-CD33A and SGN-LIV1A Programs and Breakthroughs in Research to Develop Highly Stable Linkers and More Potent Chemotypes –

– AACR Highlights Phase 1 Data for Genentech’s DMUC5754A, an ADC for Ovarian Cancer Utilizing Seattle Genetics’ Technology –

BOTHELL, Wash.–(BUSINESS WIRE)– Seattle Genetics, Inc. (NAS: SGEN) today announced that research related to its antibody-drug conjugate (ADC) technology was presented in multiple sessions at the 104th Annual Meeting of the American Association for Cancer Research (AACR) being held in Washington, D.C. Three data presentations highlight the rapid progress being made in ADC technology and testing. This includes preclinical data evaluating ADCs using a potent and newly developed cytotoxic agent, pyrrolobenzodiazepine (PBD) dimer, against two targets, CD33 and CD70. The former, SGN-CD33A, is expected to be advanced into a phase 1 clinical trial in 2013 for patients with acute myeloid leukemia (AML). In addition, preclinical data demonstrate activity of a new ADC for metastatic breast cancer, SGN-LIV1A, utilizing the same proprietary ADC technology as ADCETRIS® (brentuximab vedotin). The company also presented research on a novel method for making highly stable linkers, an advance that is being evaluated for potential future ADCs. In addition, many of the company’s collaborators, including Genentech, Pfizer, Progenics and Genmab, are reporting preclinical and clinical data from multiple ADC programs utilizing Seattle Genetics‘ proprietary ADC technology.

“As the leader in developing ADCs for the treatment of cancer, we are focused on both the current and future technology of this important class of therapeutics. More than half of the ADCs currently in clinical development utilize our technology, and we continue to advance additional candidates, such as SGN-CD33A and SGN-LIV1A, at a rapid pace. We are also looking at ways to enhance the next generation of ADCs, and believe that new potent cytotoxic agents such as PBD dimers, advances in antibody technology such as engineered cysteine antibodies (EC-mAbs), and highly stable linkers are part of that future,” said Jonathan Drachman, M.D., Senior Vice President, Research and Translational Medicine at Seattle Genetics. “We are driven to test these ADC advances quickly because cancer patients need new options to fight this relentless disease.”

ADCs are designed to harness the targeting ability of antibodies to deliver cell-killing agents directly to cancer cells. …read more

Source: FULL ARTICLE at DailyFinance

Cisco Systems Sinks in Sympathy

By Evan Niu, CFA, The Motley Fool

Filed under:

Shares of networking giant Cisco Systems are particularly weak today, having lost as much as 5% today and lagging the broader market. The reason for the pessimism is that networking peer F5 Networks announced preliminary figures last night that left a lot to be desired and have negative implications for the broader sector.

F5 expects revenue in the first quarter to be $350.2 million, far below the range of $370 million to $380 million that it had previously forecast. Both GAAP and non-GAAP earnings per share came in below expectations.

CEO John McAdam said the weakness was attributed to revenue shortfalls in the North American market, while sales in Europe, the Middle East, and Asia — collectively known as EMEA — were somewhat disappointing, too. Business in Japan and the Asia-Pacific region were on target. Telecommunications buying was down along with U.S. federal sales, the latter of which is related to sequestration.

On the ensuing conference call, McAdam said a lot of the sales shortfalls were related to timing issues, downplaying fears that the market for its application-delivery controller, or ADC, is maturing. Mizuho Securities analyst Joanna Makris believes F5 is losing some of its pricing power due to intensifying competition.

Rival ADC vendor Radware also issued disappointing preliminary results this morning, with its own revenue projected at $45 million — also below its guidance. Radware said sales were strong in the U.S. market but cited weakness in EMEA and China for its weakness.

These two preliminary releases point to headwinds in the broader networking sector, and Cisco is just one of many networking companies under pressure today as investors digest the gloomy implications for the industry.

Last quarter, product sales were 78% of revenue, and the Americas geographical segment pitched in 59% to the top line. Any slowdown in IT spending, particularly related to the sequestration, will inevitably weigh on Cisco’s results.

Once a highflying tech darling, Cisco is now on the radar of value-oriented dividend lovers. Get the lowdown on the routing juggernaut in The Motley Fool’s premium report. Click here now to get started.

var FoolAnalyticsData = FoolAnalyticsData || []; FoolAnalyticsData.push({ eventType: “TickerReportPitch”, contentByline: “Evan Niu, CFA“, …read more

Source: FULL ARTICLE at DailyFinance

Compugen Discloses Focused Target Discovery Program for Antibody-Drug Conjugate Cancer Therapy

By Business Wirevia The Motley Fool

Filed under:

Compugen Discloses Focused Target Discovery Program for Antibody-Drug Conjugate Cancer Therapy


Second program follows initial program that resulted in discovery of multiple novel immune checkpoint molecules and establishment of Pipeline Program


Initial discoveries from new program anticipated before year-end

TEL AVIV, Israel–(BUSINESS WIRE)– Compugen Ltd. (NASDAQ: CGEN) disclosed today the initiation of its second focused discovery program, aimed at identification of novel targets for antibody-drug conjugate (ADC) cancer therapy focusing on clinical situations with poor survival rates and/or recurrent cancers. This second program follows Compugen’s successful initial focused discovery program for novel immune checkpoint proteins, a number of which have been incorporated in the Company’s Pipeline Program as Fc fusion protein drugs for immunology and/or as therapeutic targets for monoclonal antibody (mAb) drugs for cancer immunotherapy.

Cancer therapy through ADCs, whereby the antibody delivers a cytotoxic drug directly and specifically to the cancer cell in order to induce direct killing of the cells, addresses an area of high unmet medical need and is of great interest to the pharma industry. However, the lack of suitable ADC targets is a major problem. This provides an opportunity for Compugen to serve as a key source of such potential targets and their mAbs.

Dr. Anat Cohen-Dayag, president and CEO of Compugen, stated, “Concurrent with our further research and development activities and collaboration discussions involving our leading Pipeline Program product candidates, we are pleased to disclose this second focused discovery effort, which was a previously stated objective for 2013. Based on the success of our first such effort, we expect initial ADC target discoveries to be added to our pipeline by yearend, thus further expanding the scope and diversity of the cancer therapy arm of our pipeline.”

The new discovery platform is designed to provide hypothesis-driven analysis of complex sets of expression and clinical data to predict proteins that can serve as novel mAb targets. The platform is based on the integration of multiple proprietary systems, tools, and algorithms from Compugen’s existing predictive discovery infrastructure with additional new specialized algorithms and queries geared towards ADC target discovery. Through the use of this discovery platform, utilizing data from numerous clinically …read more
Source: FULL ARTICLE at DailyFinance

Microchip Expands PIC24 Lite Microcontroller Portfolio with Advanced Analog Integration and 5V Opera

By Business Wirevia The Motley Fool

Filed under:

Microchip Expands PIC24 Lite Microcontroller Portfolio with Advanced Analog Integration and 5V Operation

New PIC24 Lite MCUs Feature On-Chip Op Amps, 8-bit DACs, 12-bit ADC, Flexible PWM Modules and eXtreme Low Power Technology for Cost-Sensitive Automotive, Consumer, Medical and Industrial Applications

CHANDLER, Ariz.–(BUSINESS WIRE)– Microchip Technology Inc. (NAS: MCHP) , a leading provider of microcontroller, mixed-signal, analog and Flash-IP solutions, today announced a new addition to its 16-bit PIC® microcontroller (MCU) portfolio with the low cost PIC24F “KM” family. This family offers up to 16 KB Flash, 2 KB RAM and 512B EEPROM, along with advanced analog integration, in low pin-count options for cost-sensitive automotive, consumer, medical and industrial applications.

Watch a short video: http://www.microchip.com/get/99E7

The PIC24F “KM” family provides a new level of integrated analog functionality such as a 12-bit ADC with threshold detection, 8-bit DACs for analog control loops and precision comparator references, and op amps to assist in sensor amplifications. The PIC24 “KM” MCUs are the first to feature the new Multiple-output Capture Compare PWM Module (MCCP) and Single-output Capture Compare PWM Module (SCCP) peripherals, which include integrated timers and advanced PWM control to enable motor-control, power-supply and lighting applications. The MCCP and SCCP modules combine timers, input captures, output compare and PWM functions in a single time base for optimal flexibility. These modules include 16/32-bit timer support, and can operate from a high-speed clock for higher resolution due to their ability to operate asynchronously. They also allow for automatic operations during sleep mode, to optimize power consumption.

This is also the first PIC24 family to offer a Configurable Logic Cell (CLC) for increased on-chip interconnection of peripherals. The CLC module helps in creating custom real-time logic functions on-chip and is supported by the CLC configuration tool, which helps in coding the circuit graphically instead of in assembly or C, thereby saving time for the programmers.

In addition to advanced peripheral integration, the “KM” family includes support for both 3V and 5V applications. Many customers prefer 3V operation for portable, battery-operated applications, and the 3V “KM” products all include eXtreme Low Power (XLP) for optimal battery life. Other customers prefer 5V operation with the PIC24FV16KM product variants, for applications where more dynamic range, noise immunity and robustness are the key factors. The PIC24F “KM” with its extreme low power and advanced analog integration, is an excellent solution for customers working on cost-sensitive applications, such as flow meters, smoke detectors, stepper and BLDC motors, LED dimming, battery charging, environmental …read more
Source: FULL ARTICLE at DailyFinance

Cash Dividend On The Way From Agree Realty Corp.

By DividendChannel.com

Looking at the universe of stocks we cover at Dividend Channel, on 3/26/13, Agree Realty Corp. (NYSE: ADC) will trade ex-dividend, for its quarterly dividend of $0.41, payable on 4/9/13. As a percentage of ADC‘s recent stock price of $27.77, this dividend works out to approximately 1.48%, so look for shares of Agree Realty Corp. to trade 1.48% lower ? all else being equal ? when ADC shares open for trading on 3/26/13.
Click here to learn which 25 S.A.F.E. dividend stocks should be on your radar screen » or click here to find out which 9 other stocks going ex-dividend you should know about, at DividendChannel.com » …read more
Source: FULL ARTICLE at Forbes Markets

Zilog Announces the New MCU Based Battery Charging Reference Design

By Business Wirevia The Motley Fool

Filed under:

Zilog Announces the New MCU Based Battery Charging Reference Design


High-Performance Design Solutions Offering Digital Improved Battery Management Technology

MILPITAS, Calif. & BIEL, Switzerland–(BUSINESS WIRE)– Zilog, a wholly-owned subsidiary of IXYS Corporation (NAS: IXYS) and a pioneer supplier of application-specific, embedded microcontroller (MCU) system-on-chip (SoC) solutions for industrial and consumer power management applications, is introducing its new Buck Converter Battery Charger Reference Design that employs Zilog’s Z8F042A MCU to control a step-down DC-DC converter (also known as a buck converter) that acts as a regulated power source.

This buck converter battery charger hardware is capable of regulating charger output in a number of modes, such as constant voltage or constant current with set current limits. The charger can be viewed as a complete control system. The type and capacity of the battery determines the mode of operation of the battery controller. The voltage and current set points are also determined by the type and capacity of the battery. All battery control loop operations can be controlled by the user via the Z8F042A MCU‘s UART block and feedback is provided in the HyperTerminal console. Additionally, LEDs provide a visual status of the charging process.

This low-cost reference design demonstrates a lithium ion battery charger consisting of a Z8F042A MCU and a buck converter. The charging process utilizes the highly accurate ADC peripheral and alternates between current and voltage monitoring which is controlled in the background software routine, allowing for the UART to be processed in the main function. With the provided hyper terminal GUI, the user can enter desired set-voltages and set-currents. A proportional/integral (PI) control loop is used to charge the battery and to monitor the battery voltage after the charging process is completed. To save memory resources, the provided UART does not implement the STDIO.H libraries. Instead, a simple UART using only integer values is used.

“This battery charger reference design allows operation either via UART or an external 5-15V power supply. The advantage of this battery charger implementation is in the efficient utilization of the Zilog MCU resources, allowing for low cost digital power management solution, which is flexible and adaptable to different batteries,” commented Steve Darrough, Zilog’s VP of Marketing.

Zilog’s Buck Converter Battery Charger Reference Design is now available for customers that place orders through Zilog’s online store. …read more
Source: FULL ARTICLE at DailyFinance

Freescale Introduces Healthcare Analog Front End Reference Platform

By Business Wirevia The Motley Fool

Filed under:

Freescale Introduces Healthcare Analog Front End Reference Platform

Comprehensive platform, with hardware, schematics and software, helps decrease development time for healthcare applications

SHANGHAI–(BUSINESS WIRE)– The global proliferation of portable medical devices is making medical technology more accessible to consumers and transforming the healthcare industry by providing previously unavailable technology to end users, often in their own home. Medical device manufacturers are facing the challenges of the consumer marketplace including its price sensitivity and time-to-market pressure. To help simplify product development, reduce cost and speed time to market, Freescale Semiconductor (NYS: FSL) is introducing a Healthcare Analog Front End (AFE) reference platform that includes hardware, schematics and software for easy prototyping.

The Freescale Healthcare AFE reference platform is a highly integrated HW/SW development platform, that helps reduce system cost, board size and complexity. The platform is built around the Kinetis K53 MCU which includes an integrated analog front end (AFE) featuring everything needed to capture biometric sensor data. The integrated AFE contains a precise voltage reference, four high performance amplifiers and two high-resolution ADC and DAC modules. (Photo: Business Wire)

The global medical device industry is growing rapidly and is expected to reach $228 billion by 2015, up from $164 billion in 2010, according to a recent industry research report by Espicom. According to Gartner, portable consumer medical devices, such as blood glucose monitors, blood pressure monitors, insulin pumps and heart rate monitors, represent the fastest-growing segment in that market.

“The continued consumerization of healthcare is putting significant pressure on the medical device engineering community,” said Steven Dean, director of vertical solutions marketing at Freescale. “These engineers are expected to complete designs in a few months, and they appreciate anything vendors like Freescale can do to make the process easier and faster. Our healthcare-specific AFE reference platform allows engineers and external design firms to more easily prototype products and complete more projects in a shorter timeframe.”

Reducing development costs

The Freescale Healthcare AFE reference platform is a highly integrated HW/SW development platform, that helps reduce system cost, board size and complexity. The platform is built around the Kinetis K53 MCU which includes an integrated analog front end (AFE) featuring everything needed to capture biometric sensor data. The integrated AFE contains a precise voltage reference, four high performance amplifiers and …read more
Source: FULL ARTICLE at DailyFinance

Seattle Genetics Submits Supplemental BLA to FDA for Retreatment and Extended Duration of Therapy wi

By Business Wirevia The Motley Fool

Filed under:

Seattle Genetics Submits Supplemental BLA to FDA for Retreatment and Extended Duration of Therapy with ADCETRIS ® (Brentuximab Vedotin) in Relapsed Hodgkin Lymphoma and Systemic ALCL

BOTHELL, Wash.–(BUSINESS WIRE)– Seattle Genetics, Inc. (NAS: SGEN) announced today that it has submitted a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) supporting the use of ADCETRIS (brentuximab vedotin) for retreatment and extended duration beyond 16 cycles of therapy in relapsed Hodgkin lymphoma (HL) and systemic anaplastic large cell lymphoma (sALCL). ADCETRIS is an antibody-drug conjugate (ADC) directed to CD30, a defining marker of HL and sALCL, that was granted accelerated approval by the FDA in August 2011 for relapsed HL and relapsed sALCL.

“The sBLA submission includes data demonstrating ADCETRIS activity in managing HL and sALCL when used in the retreatment setting, as well as beyond the 16 cycles described in our current label, while retaining a manageable safety profile,” said Clay B. Siegall, Ph.D., President and Chief Executive Officer of Seattle Genetics. “Our goal is to broaden the ADCETRIS U.S. labeling claims to provide both patients and physicians the opportunity to incorporate ADCETRIS into additional HL and sALCL treatment settings. The sBLA submission includes data that support these uses and we look forward to the regulatory outcome.”

The sBLA is based on results from a phase II clinical trial with two treatment arms. One arm evaluated retreatment with ADCETRIS in patients who previously responded to treatment with ADCETRIS, then discontinued treatment and subsequently had disease progression or relapse. The other arm allowed treatment extension and evaluated prolonged treatment with ADCETRIS beyond 16 cycles of therapy. The sBLA submission includes updated data sets from this phase II trial. Preliminary data from this trial were previously reported at the 2011 American Society of Hematology (ASH) Annual Meeting and at the 2012 American Society of Clinical Oncology (ASCO) Annual meeting.

At the 2012 ASCO Annual Meeting, retreatment data from the phase II trial were reported from 23 patients, including one patient who was treated twice. Patients had received a median of four prior systemic therapies, including ADCETRIS. Of 23 evaluable patients, 70 percent (16 of 23) achieved an objective response after retreatment with ADCETRIS, including nine complete remissions and seven partial remissions. Median duration of retreatment objective response was 8.8 months. Among retreated HL patients, nine of 16 (56 percent) achieved an objective response. Among retreated sALCL patients, seven of eight (88 percent) achieved an objective response. The most common adverse events were peripheral neuropathy (46 percent), nausea (42 percent), fatigue (38 percent), diarrhea (33 percent) and fever (29 percent).

…read more
Source: FULL ARTICLE at DailyFinance

DaVita Clinical Research Presents Research Results at the 33rd Annual Dialysis Conference

By Business Wirevia The Motley Fool

Filed under:

DaVita Clinical Research Presents Research Results at the 33rd Annual Dialysis Conference

SEATTLE–(BUSINESS WIRE)– DaVita Clinical Research® (DCR®), a specialty contract research organization with services spanning the full spectrum of drug and device development, presented research results at the 33rd Annual Dialysis Conference (ADC)in Seattle, March 9-12, 2013.

This international conference has become an influential annual meeting in the dialysis and nephrology communities. The 2012 meeting attracted over 1,800 participants from more than 40 countries.

Researchers from DaVita®, the dialysis division of DaVita Healthcare Partners Inc., and DCR presented results from a number of innovative clinical improvement programs originating from DaVita and its research partners. DCR provides a collaborative bridge between DaVita’s health care community and the academic, pharmaceutical and biotech research community. DCR and DaVita share a dedication to improving the health and quality of life for kidney care patients.

“Our goal at DaVita is to try to improve our patients’ quality of life. Research is a critical vehicle to achieve that end,” said Mahesh Krishnan, M.D., M.P.H., M.B.A., F.A.S.N., vice president of clinical research. “The work presented at ADC is intended to lead to better clinical outcomes and better quality of life for chronic kidney disease and end-stage renal disease patients around the world.”

ADC featured the following oral presentations by John Moran, M.D., F.A.C.P., vice president of medical affairs at DaVita:

  • Urgent-Start Peritoneal Dialysis: A Clinical Process Improvement Report – Monday, March 11. Slide Forum IV, Clinical Studies & Experiences Part B.
  • Implementation of Alcayis Protocol Markedly Improves Peritonitis Rates – Monday, March 11. Slide Forum IV, Clinical Studies & Experiences Part B.
  • Decreasing Peritonitis Rate in PD Resulting in Lower Mortality and Technique Failure – Monday, March 11. Slide Forum I, Quality Improvement.

ADC also featured the following poster presentation:

Use The Terminal To Test Arduino Is Working.

By wisecracker

Hi all…

(Apologies for any typos at all.)

This is a step by step _script_ to check if your Arduino is talking to your Linux or Macbook Pro computer using the Terminal…

It works on at least 3 Linux flavours and now the Macbook Pro

I hope you find it useful as a simple check for your Arduino setup…

This is issued as Public Domain.

The “Test.pde” is the code to program the Arduino with.
My Arduino programming SW is old and I am aware that the “Test.pde” script will not compile on current Arduino programming SW. I am assuming you will know what to do with it…

Code:

A basic, terminal, test sequence to check that the Arduino Diecimila board is _talking_ to your computer.

Step by step testing inside a Linux , OR, Macbook Pro Terminal usage for the USB Arduino Diecimila Board...
Issued as completely Public Domain by B.Walker, G0LCU, 2011-2013.

Common to both systems:-
------------------------

1) Boot up to your Linux flavour or Macbook Pro as root, (or run in a root Terminal).
2) Temporarily disable any net access or use a stand-alone machine.
3) Plug in the USB Arduino board.
4) Open up a, (root), Terminal and clear the screen.
5) clear

Linux flavours first:-
----------------------
6) Check that you have a device as ttyUSB?
IMPORTANT NOTE: Arduino boards are now detected as ttyACM? so although NOT tested this might still work...
If this is the case then replace ttyUSB? with ttyACM? below...

7) ls /dev
NOTE:- ? above will probably be 0.
8) If ttyUSB0, (to 7), appears then carry on; otherwise ignore the remainder of this text.

NOTE:- Assuming the device is ttyUSB0 from now on, change below if needed to your ttyUSBx device.
9) Place a wire link between ANALOG 0 and the 3.3 V terminals, OR,
A potentiometer wired, one end to ground, GND, the other end to +5V and the wiper to ANALOG 0...

NOTE:- 'chmod' is probably not really needed but added for fullness!
10) chmod 666 /dev/ttyUSB0

11) Set up the on board serial I/O to 9600bps and RAW data transfer for PCLinuxOS and Debian.
12) stty -F /dev/ttyUSB0 1200
13) stty -F /dev/ttyUSB0 raw

14) Now start printing characters to the screen...
15) cat < /dev/ttyUSB0
NOTE:- The wire link characters will be from about 168 to 174 decimal allowing for bit error of the Arduino ADC.

16) Remove and replace the wire link from ANALOG 0 and GND or ANALOG 0 and 5 V too, OR,
A potentiometer wired, one end to ground, GND, the other end to +5V and the wiper to ANALOG 0...
17) Press 'Ctrl-C' to stop any characters being printed to the Terminal.
18) Unplug the USB Arduino board.
19) Power down the computer IF REQUIRED.

Now the Macbook Pro:-
---------------------
6) Now find the device name, mine is tty.usbserial-A7007cvs, yours will probably be much different...

7) ls /dev
8) If you have a new tty* note its name then carry on, otherwise ignore the rest of this text.
(I will use my device name for this example.)

9) Place a wire link between ANALOG 0 and the 3.3 V terminals, OR,
A potentiometer wired, one end to ground, GND, the other end to +5V and the wiper to ANALOG 0...

NOTE:- 'chmod' is probably not really needed but added for fullness!
10) chmod 666 /dev/tty.usbserial-A7007cvs

11) Now start printing characters to the screen...
(The command stty does NOT work for this on the Macnook Pro so revert to the command cu instead.)
12) cu -l /dev/tty.usbserial-A7007cvs -s 9600

13) Ctrl-C does not work so just close down the Terminal COMPLETELY.
14) Unplug tha Arduino board.
15) Power down the computer IF REQUIRED.

=============================================================

This is the "test.pde" code for the Arduino Diecimila board:-
-------------------------------------------------------------

/* Test.pde */
/* Using the Arduino as a DEMO single channel ADC for WinUAE. */
/* For use with AF2005 or greater. This is just demonstration code */
/* only and shows that I/O is possible through WinUAE by other means. */

/* Set up a variable 1 byte in size for basic analogue input. */
int analogue0 = 0;

void setup() {
/* open the serial port at 9600 bps. This rate is used for purely */
/* for simplicity only. */
Serial.begin(9600);

/* Set the analogue voltage reference, DEFAULT is 5V in this case. */
analogReference(DEFAULT);
}

void loop() {
/* Read the 10 bit analogue voltage on analogue input 0. */
analogue0 = analogRead(0);
/* Convert to a byte value by dividing by 4. */
analogue0 = analogue0/4;

/* Send to the Serial Port the byte value. */
Serial.print(analogue0, BYTE);

/* Delay 500 milliseconds before taking the next reading. */
delay(500);
}

=============================================================

Enjoy finding simple solutions to often very difficult problems...

Bazza, G0LCU...


Source: FULL ARTICLE at The UNIX and Linux Forums